Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Dyne Therapeutics (DYN) Financials

Dyne Therapeutics logo
$13.75 +0.11 (+0.81%)
Closing price 04:00 PM Eastern
Extended Trading
$13.82 +0.07 (+0.55%)
As of 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Dyne Therapeutics

Annual Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -15 -59 -149 -168 -236 -317
Consolidated Net Income / (Loss)		 -15 -59 -149 -168 -236 -317
Net Income / (Loss) Continuing Operations		 -15 -59 -149 -168 -236 -317
Total Pre-Tax Income 		-15 -59 -149 -168 -236 -317
Total Operating Income		 -14 -59 -150 -171 -242 -344
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 59 150 171 242 344
Selling, General & Admin Expense		 2.79 13 29 28 31 62
Research & Development Expense		 11 45 121 143 211 281
Total Other Income / (Expense), net		 -1.03 0.11 0.73 2.86 6.23 26
Interest & Investment Income		 0.29 0.06 0.74 2.92 7.64 27
Other Income / (Expense), net		 -1.32 0.45 -0.01 -0.05 -1.42 -0.45
Basic Earnings per Share		 ($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Weighted Average Basic Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M
Diluted Earnings per Share		 ($6.08) ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Weighted Average Diluted Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M
Weighted Average Basic & Diluted Shares Outstanding		 2.44M 14.40M 50.90M 51.98M 59.68M 94.14M

Quarterly Income Statements for Dyne Therapeutics

This table shows Dyne Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -38 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Consolidated Net Income / (Loss)		 -39 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Net Income / (Loss) Continuing Operations		 -40 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Total Pre-Tax Income 		-39 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Total Operating Income		 -40 -45 -67 -62 -68 -69 -72 -106 -97 -122 -116
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 40 45 67 62 68 69 72 106 97 122 116
Selling, General & Admin Expense		 6.96 7.93 7.61 7.02 8.84 25 9.70 13 15 16 17
Research & Development Expense		 33 38 59 55 59 45 62 93 82 106 99
Total Other Income / (Expense), net		 1.09 1.28 1.83 2.06 1.05 3.51 6.86 8.53 7.57 7.01 4.93
Interest Expense		 - - - - - - 0.00 - - - 0.09
Interest & Investment Income		 1.34 1.49 2.21 2.19 1.75 3.00 7.05 9.28 7.59 7.10 6.63
Other Income / (Expense), net		 -0.26 -0.22 -0.37 -0.13 -0.70 0.51 -0.19 -0.74 -0.03 -0.09 -1.60
Basic Earnings per Share		 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97)
Weighted Average Basic Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Diluted Earnings per Share		 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97)
Weighted Average Diluted Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Weighted Average Basic & Diluted Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M

Annual Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 6.51 288 -100 -29 -51 313
Net Cash From Operating Activities		 -12 -47 -120 -154 -188 -292
Net Cash From Continuing Operating Activities		 -12 -47 -120 -154 -188 -292
Net Income / (Loss) Continuing Operations		 -15 -59 -149 -168 -236 -317
Consolidated Net Income / (Loss)		 -15 -59 -149 -168 -236 -317
Depreciation Expense		 0.27 0.70 1.09 1.68 1.67 1.67
Amortization Expense		 0.00 0.08 2.58 1.28 -1.10 -3.60
Non-Cash Adjustments To Reconcile Net Income		 1.35 6.14 14 17 21 46
Changes in Operating Assets and Liabilities, net		 1.41 5.11 12 -5.38 26 -19
Net Cash From Investing Activities		 -1.65 -46 -138 87 83 -204
Net Cash From Continuing Investing Activities		 -1.65 -46 -138 87 83 -204
Purchase of Property, Plant & Equipment		 -1.65 -1.16 -3.62 -3.07 -0.73 -2.38
Purchase of Investments		 0.00 -45 -237 -121 -44 -317
Sale and/or Maturity of Investments		 - 0.00 102 211 128 116
Net Cash From Financing Activities		 20 381 158 37 54 810
Net Cash From Continuing Financing Activities		 20 381 158 37 54 810
Issuance of Common Equity		 0.00 246 157 37 52 773
Other Financing Activities, net		 0.00 -0.42 0.58 0.53 1.95 37

Quarterly Cash Flow Statements for Dyne Therapeutics

This table details how cash moves in and out of Dyne Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents		 27 8.97 -14 -37 -8.66 150 336 -76 -97 37 13
Net Cash From Operating Activities		 -29 -47 -56 -51 -35 -79 -55 -75 -84 -106 -95
Net Cash From Continuing Operating Activities		 -29 -47 -56 -51 -35 -78 -55 -75 -84 -106 -95
Net Income / (Loss) Continuing Operations		 -39 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Consolidated Net Income / (Loss)		 -39 -44 -65 -60 -67 -66 -65 -97 -90 -115 -111
Depreciation Expense		 0.40 0.41 0.43 0.43 0.40 0.39 0.40 0.44 0.45 0.50 0.50
Amortization Expense		 0.03 -0.18 -0.36 -0.37 -0.19 - -1.27 -0.98 -0.84 -0.62 -0.46
Non-Cash Adjustments To Reconcile Net Income		 4.05 4.95 4.99 5.04 5.90 20 6.86 8.88 11 13 10
Changes in Operating Assets and Liabilities, net		 5.16 -7.92 4.20 4.50 26 -33 4.24 14 -5.09 -3.60 5.64
Net Cash From Investing Activities		 19 27 17 13 26 -180 11 -19 -16 1.46 6.77
Net Cash From Continuing Investing Activities		 19 27 17 13 26 -182 11 -19 -16 1.46 6.77
Purchase of Property, Plant & Equipment		 -0.52 -0.23 -0.25 -0.17 -0.08 -0.19 -0.86 -0.25 -1.08 -0.98 -0.06
Purchase of Investments		 -26 -17 -18 -9.58 - -181 -26 -57 -53 -66 -41
Sale and/or Maturity of Investments		 46 44 35 23 26 0.00 38 38 38 68 48
Net Cash From Financing Activities		 37 29 25 0.45 0.15 408 380 18 3.64 141 101
Net Cash From Continuing Financing Activities		 37 29 25 0.45 0.15 408 380 18 3.64 141 101
Other Financing Activities, net		 0.34 0.59 0.76 0.45 0.15 11 4.28 18 3.64 0.59 1.97

Annual Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 16 353 426 306 165 691
Total Current Assets		 15 349 382 266 129 659
Cash & Equivalents		 15 301 201 172 122 435
Short-Term Investments		 0.00 44 176 84 1.47 207
Prepaid Expenses		 0.13 3.77 5.82 9.58 6.28 17
Plant, Property, & Equipment, net		 1.49 1.95 4.68 5.95 4.78 5.40
Total Noncurrent Assets		 0.19 2.30 39 35 31 27
Other Noncurrent Operating Assets		 0.19 2.30 39 35 31 27
Total Liabilities & Shareholders' Equity		 16 353 426 306 165 691
Total Liabilities		 2.40 11 57 54 74 61
Total Current Liabilities		 2.36 11 29 28 51 42
Accounts Payable		 1.26 3.44 4.03 5.26 23 6.56
Accrued Expenses		 1.10 7.53 21 18 23 31
Other Current Liabilities		 - 0.00 3.89 4.61 4.72 4.85
Total Noncurrent Liabilities		 0.04 0.00 29 26 23 19
Long-Term Debt		 - - - - - 0.00
Other Noncurrent Operating Liabilities		 - 0.00 29 26 23 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 342 368 252 91 630
Total Preferred & Common Equity		 14 342 368 252 91 630
Preferred Stock		 27 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -13 342 368 252 91 630
Common Stock		 6.35 422 597 650 724 1,580
Retained Earnings		 -20 -79 -228 -397 -633 -950
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.03 -0.27 -0.57 0.00 0.01

Quarterly Balance Sheets for Dyne Therapeutics

This table presents Dyne Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025
Period end date 6/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025
Total Assets		 340 289 251 205 522 826 769 721 729
Total Current Assets		 298 249 213 168 488 792 736 690 698
Cash & Equivalents		 136 181 168 130 272 608 532 472 485
Short-Term Investments		 156 57 40 28 182 171 192 205 199
Prepaid Expenses		 6.10 11 5.44 10 35 13 13 12 14
Plant, Property, & Equipment, net		 5.48 5.57 5.36 5.11 4.58 5.02 4.90 5.75 5.68
Total Noncurrent Assets		 37 34 33 32 30 29 28 26 23
Other Noncurrent Operating Assets		 37 34 33 32 30 29 28 26 23
Total Liabilities & Shareholders' Equity		 340 289 251 205 522 826 769 721 729
Total Liabilities		 53 47 45 53 44 51 63 52 158
Total Current Liabilities		 26 22 20 30 22 30 43 34 41
Accounts Payable		 6.97 8.77 2.72 3.55 7.21 1.89 6.16 7.02 14
Accrued Expenses		 13 8.17 13 21 10 23 32 22 22
Other Current Liabilities		 5.49 4.64 4.71 4.71 4.76 4.78 4.81 5.11 5.00
Total Noncurrent Liabilities		 27 25 24 24 22 21 20 18 116
Long-Term Debt		 - - - - - - - - 99
Other Noncurrent Operating Liabilities		 27 25 - - 22 - 20 - 17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 287 242 207 152 478 775 706 669 571
Total Preferred & Common Equity		 287 242 207 152 478 775 706 669 571
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 287 242 207 152 478 775 706 669 571
Common Stock		 605 683 713 718 1,176 1,539 1,565 1,734 1,747
Retained Earnings		 -316 -441 -506 -566 -698 -763 -860 -1,065 -1,176
Accumulated Other Comprehensive Income / (Loss)		 -1.16 -0.20 -0.06 -0.01 -0.13 -0.24 0.48 0.24 0.25

Annual Metrics And Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -285.95% -154.90% -14.82% -44.60% -42.49%
EBIT Growth		 0.00% -284.16% -157.80% -13.99% -42.43% -41.37%
NOPAT Growth		 0.00% -324.18% -155.81% -13.96% -41.65% -42.01%
Net Income Growth		 0.00% -300.01% -151.18% -12.60% -40.36% -34.54%
EPS Growth		 0.00% 32.07% 29.06% -10.24% -22.29% 14.68%
Operating Cash Flow Growth		 0.00% -293.00% -157.08% -28.51% -22.46% -55.38%
Free Cash Flow Firm Growth		 0.00% 0.00% -157.33% -24.91% -13.63% -84.01%
Invested Capital Growth		 0.00% -394.46% -184.15% 56.44% -771.93% 60.92%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -18.25% 0.00% -13.14% -9.26%
EBIT Q/Q Growth		 0.00% 0.00% -18.45% 0.00% -12.98% -9.11%
NOPAT Q/Q Growth		 0.00% 0.00% -18.44% 0.00% -12.83% -9.36%
Net Income Q/Q Growth		 0.00% 0.00% -18.34% 0.00% -13.36% -7.78%
EPS Q/Q Growth		 0.00% 0.00% -1,727.78% 0.00% -10.34% 5.60%
Operating Cash Flow Q/Q Growth		 0.00% -52.56% -7.20% 0.00% -3.19% -20.30%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -1,986.84% 15.84% -41.16%
Invested Capital Q/Q Growth		 0.00% 0.00% -227.01% 0.00% -279.41% 31.45%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 101.54% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.09% 100.58% 99.51% 98.29% 96.86% 92.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -105.86% -33.35% -42.02% -54.18% -137.31% -88.03%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 101.01% -30.79% -42.02% -54.18% -137.31% -88.03%
Return on Equity Simple (ROE_SIMPLE)		 -105.86% -17.36% -40.55% -66.61% -258.44% -50.40%
Net Operating Profit after Tax (NOPAT)		 -9.68 -41 -105 -120 -170 -241
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -35.41% -10.21% -12.27% -15.31% -35.04% -20.04%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -47.42% -185.68% -38.22%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -15 -58 -150 -171 -244 -344
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -57 -146 -168 -243 -346
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.79 1.66 2.38 8.94 3.81
Price to Tangible Book Value (P/TBV)		 0.00 2.79 1.66 2.38 8.94 3.81
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.01 -1.02 -1.02 -1.10 -1.06
Leverage Ratio		 1.17 1.04 1.10 1.18 1.37 1.19
Compound Leverage Factor		 1.15 1.04 1.09 1.16 1.33 1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 195.42% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -95.42% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 54.38 52.50 5.48 3.95 -3.03 20.93
Noncontrolling Interest Sharing Ratio		 195.42% 7.70% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 6.26 31.83 13.31 9.46 2.53 15.60
Quick Ratio		 6.21 31.49 13.11 9.11 2.41 15.20
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -39 -100 -124 -141 -260
Operating Cash Flow to CapEx		 -718.52% -4,005.86% -3,304.67% -5,009.62% -25,810.43% -12,305.09%
Free Cash Flow to Firm to Interest Expense		 0.00 -97.73 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -117.44 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -120.38 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.60 -2.95 -8.37 -3.65 -32 -12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.35 -5.43 4.73 -28 19
Enterprise Value (EV)		 246 609 236 344 693 1,755
Market Capitalization		 233 954 613 600 816 2,398
Book Value per Share		 ($5.48) $7.53 $7.15 $4.86 $1.49 $6.19
Tangible Book Value per Share		 ($5.48) $7.53 $7.15 $4.86 $1.49 $6.19
Total Capital		 14 342 368 252 91 630
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -15 -345 -377 -256 -123 -642
Capital Expenditures (CapEx)		 1.65 1.16 3.62 3.07 0.73 2.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.23 -7.19 -23 -19 -45 -25
Debt-free Net Working Capital (DFNWC)		 12 338 354 238 78 617
Net Working Capital (NWC)		 12 338 354 238 78 617
Net Nonoperating Expense (NNE)		 5.18 18 44 48 66 77
Net Nonoperating Obligations (NNO)		 -15 -345 -377 -256 -123 -642
Total Depreciation and Amortization (D&A)		 0.27 0.78 3.67 2.96 0.57 -1.93
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 51.46M 51.64M 56.34M 59.68M 94.14M
Adjusted Diluted Earnings per Share		 $0.00 ($4.13) ($2.93) ($3.23) ($3.95) ($3.37)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 51.46M 51.64M 51.98M 59.68M 94.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.13) ($2.93) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.40M 50.90M 51.98M 59.68M 94.14M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.68 -41 -105 -120 -170 -241
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 -146.96 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -103.67 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -149.89 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -106.60 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Dyne Therapeutics

This table displays calculated financial ratios and metrics derived from Dyne Therapeutics' official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -31.53% -29.22% -49.64% -70.59% -50.20% -8.93% -71.56% -43.02% -79.56% -63.54%
EBIT Growth		 0.00% -28.38% -27.23% -47.56% -69.28% -50.29% -7.52% -70.52% -42.03% -78.38% -62.69%
NOPAT Growth		 0.00% -27.05% -26.50% -47.29% -68.61% -52.11% -7.83% -69.67% -43.46% -76.95% -60.91%
Net Income Growth		 0.00% -24.18% -24.09% -45.49% -71.63% -48.57% -0.31% -61.31% -34.37% -75.72% -70.28%
EPS Growth		 0.00% -13.04% -6.93% -23.75% -50.68% -3.85% 35.19% 3.03% 18.18% -29.63% -38.57%
Operating Cash Flow Growth		 0.00% 7.55% -80.02% -18.22% -19.92% -67.43% 1.39% -47.48% -140.92% -34.83% -72.60%
Free Cash Flow Firm Growth		 -704.89% 48.50% -395.04% -166.58% 41.44% -211.13% 41.04% 37.87% -354.44% -2.40% -7.66%
Invested Capital Growth		 56.44% -72.02% 591.04% 0.00% -771.93% 558.11% -26.31% -202.28% 60.92% -60.42% -193.54%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 4.04% -13.70% -47.51% 7.02% -9.39% -0.12% -6.16% -46.44% 8.81% -25.69% 4.26%
EBIT Q/Q Growth		 4.46% -13.07% -46.91% 7.02% -9.60% -0.38% -5.10% -47.46% 8.71% -26.07% 4.14%
NOPAT Q/Q Growth		 5.05% -13.25% -46.79% 6.69% -8.70% -2.17% -4.06% -46.83% 8.09% -26.02% 5.38%
Net Income Q/Q Growth		 6.18% -13.80% -46.88% 7.23% -10.68% 1.48% 0.83% -49.19% 7.81% -28.83% 3.90%
EPS Q/Q Growth		 8.75% -6.85% -38.46% 8.33% -11.11% 26.36% 13.58% -37.14% 6.25% -16.67% 7.62%
Operating Cash Flow Q/Q Growth		 31.80% -60.69% -18.62% 9.06% 30.82% -124.35% 30.14% -36.02% -13.01% -25.56% 10.57%
Free Cash Flow Firm Q/Q Growth		 -42.71% 32.25% -237.06% 18.20% 68.65% -259.97% 36.12% 13.80% -129.28% 18.89% 32.84%
Invested Capital Q/Q Growth		 0.00% 202.08% 530.16% -24.45% -279.41% 177.05% -29.44% -204.86% 31.45% 178.04% -266.75%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.41% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.68% 96.73% 96.71% 96.49% 97.44% 95.63% 90.23% 91.28% 92.18% 94.20% 94.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -54.18% -61.10% -76.65% -273.78% -137.31% -71.50% -52.46% -68.69% -88.03% -64.01% -61.32%
Cash Return on Invested Capital (CROIC)		 0.00% -1,372.22% -700.91% -1,894.77% 0.00% -1,465.59% -900.80% 0.00% 0.00% -1,538.60% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -54.18% -61.10% -76.65% -273.78% -137.31% -71.50% -52.46% -68.69% -88.03% -64.01% -61.32%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -73.04% -91.50% -136.89% 0.00% -53.84% -33.23% -41.74% 0.00% -54.88% 0.00%
Net Operating Profit after Tax (NOPAT)		 -28 -32 -47 -44 -47 -48 -50 -74 -68 -86 -81
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.39% -4.40% -7.65% -24.75% -10.16% -4.98% -3.13% -5.40% -5.64% -5.34% -4.43%
Return On Investment Capital (ROIC_SIMPLE)		 -11.14% - - - -51.90% -10.13% - - -10.79% -12.47% -12.09%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -40 -46 -67 -62 -68 -69 -72 -106 -97 -122 -117
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -45 -67 -62 -68 -68 -73 -107 -98 -123 -117
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.38 2.68 3.17 3.60 8.94 4.87 3.98 5.11 3.81 1.77 1.89
Price to Tangible Book Value (P/TBV)		 2.38 2.68 3.17 3.60 8.94 4.87 3.98 5.11 3.81 1.77 1.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 110.31 20.14 23.26 0.00 76.43 134.50 0.00 0.00 54.02 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.12 0.15 0.00 0.00 0.03 0.00 0.00 0.03 0.17
Long-Term Debt to Equity		 0.00 0.00 0.12 0.15 0.00 0.00 0.03 0.00 0.00 0.03 0.17
Financial Leverage		 -1.02 -0.97 -0.96 -0.88 -1.10 -0.96 -0.96 -1.00 -1.06 -0.97 -1.00
Leverage Ratio		 1.18 1.17 1.20 1.35 1.37 1.13 1.10 1.14 1.19 1.08 1.15
Compound Leverage Factor		 1.14 1.13 1.16 1.30 1.34 1.08 0.99 1.04 1.09 1.02 1.09
Debt to Total Capital		 0.00% 0.00% 10.52% 13.39% 0.00% 0.00% 2.63% 0.00% 0.00% 2.65% 14.74%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 10.52% 13.39% 0.00% 0.00% 2.63% 0.00% 0.00% 2.65% 14.74%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 89.48% 86.61% 100.00% 100.00% 97.37% 100.00% 100.00% 97.35% 85.26%
Debt to EBITDA		 0.00 0.00 -0.13 -0.11 0.00 0.00 -0.08 0.00 0.00 -0.05 -0.22
Net Debt to EBITDA		 0.00 0.00 0.94 0.63 0.00 0.00 2.78 0.00 0.00 1.66 1.32
Long-Term Debt to EBITDA		 0.00 0.00 -0.13 -0.11 0.00 0.00 -0.08 0.00 0.00 -0.05 -0.22
Debt to NOPAT		 0.00 0.00 -0.18 -0.16 0.00 0.00 -0.11 0.00 0.00 -0.07 -0.32
Net Debt to NOPAT		 0.00 0.00 1.35 0.89 0.00 0.00 3.99 0.00 0.00 2.37 1.90
Long-Term Debt to NOPAT		 0.00 0.00 -0.18 -0.16 0.00 0.00 -0.11 0.00 0.00 -0.07 -0.32
Altman Z-Score		 5.35 6.62 6.06 2.11 0.48 30.33 36.03 33.24 22.11 12.09 2.41
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.46 11.54 10.54 5.67 2.53 21.83 26.63 17.02 15.60 20.35 16.83
Quick Ratio		 9.11 11.03 10.27 5.32 2.41 20.28 26.18 16.73 15.20 20.00 16.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -33 -22 -75 -61 -19 -69 -44 -38 -87 -71 -48
Operating Cash Flow to CapEx		 -5,624.66% -20,394.78% -22,256.80% -30,300.60% -42,690.24% -41,118.85% -6,402.33% -29,497.63% -7,845.12% -10,794.39% -157,838.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -506.23
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,007.48
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,008.12
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.65 3.72 23 18 -32 25 17 -18 -12 9.70 -16
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.73 -9.59 28 18 -28 21 -6.17 -36 19 -15 -33
Enterprise Value (EV)		 344 411 473 412 693 1,873 2,326 2,883 1,755 524 497
Market Capitalization		 600 649 656 547 816 2,327 3,084 3,606 2,398 1,183 1,082
Book Value per Share		 $4.86 $4.29 $3.55 $2.49 $1.49 $5.83 $8.87 $7.03 $6.19 $5.91 $5.03
Tangible Book Value per Share		 $4.86 $4.29 $3.55 $2.49 $1.49 $5.83 $8.87 $7.03 $6.19 $5.91 $5.03
Total Capital		 252 242 231 176 91 478 796 706 630 687 670
Total Debt		 0.00 0.00 24 24 0.00 0.00 21 0.00 0.00 18 99
Total Long-Term Debt		 0.00 0.00 24 24 0.00 0.00 21 0.00 0.00 18 99
Net Debt		 -256 -238 -183 -134 -123 -454 -758 -724 -642 -659 -585
Capital Expenditures (CapEx)		 0.52 0.23 0.25 0.17 0.08 0.19 0.86 0.25 1.08 0.98 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -11 -15 -19 -45 12 -16 -31 -25 -22 -27
Debt-free Net Working Capital (DFNWC)		 238 228 193 139 78 466 763 693 617 656 656
Net Working Capital (NWC)		 238 228 193 139 78 466 763 693 617 656 656
Net Nonoperating Expense (NNE)		 11 12 18 17 19 17 15 23 22 30 30
Net Nonoperating Obligations (NNO)		 -256 -238 -183 -134 -123 -454 -758 -724 -642 -659 -588
Total Depreciation and Amortization (D&A)		 0.43 0.23 0.07 0.07 0.21 0.39 -0.87 -0.54 -0.39 -0.11 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97)
Adjusted Weighted Average Basic Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Adjusted Diluted Earnings per Share		 ($0.73) ($0.78) ($1.08) ($0.99) ($1.10) ($0.81) ($0.70) ($0.96) ($0.90) ($1.05) ($0.97)
Adjusted Weighted Average Diluted Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 51.98M 56.33M 59.84M 61.11M 59.68M 81.04M 92.51M 100.88M 94.14M 109.91M 113.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -32 -47 -44 -47 -48 -50 -74 -68 -86 -81
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,248.81
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -862.27
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,249.45
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -862.91
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Dyne Therapeutics, Inc. (NASDAQ: DYN) Financial Analysis - Last 4 Years Overview

Dyne Therapeutics continues to operate without generating revenue, reflecting its current focus on research and development rather than commercial sales. The company's financials show consistent operating losses, significant investments in R&D, and a solid liquidity position supported by equity financing.

  • Cash & Equivalents Increased: Dyne's cash and equivalents rose significantly to $485 million as of Q2 2025 from $272 million in Q1 2024, reflecting strong cash reserves to support ongoing R&D efforts.
  • Equity Financing: The company raised substantial capital through the issuance of common equity across multiple quarters, including $141 million in Q2 2025 and sizable raises in prior periods, bolstering its financial runway.
  • Stable Operating Expenses Investment: R&D expenses rose to nearly $99 million in Q2 2025 from $37 million in Q1 2023, demonstrating continued commitment to pipeline advancement and innovation.
  • Increasing Other Income: The company recorded net other income, driven partly by interest and investment income, with $4.9 million in Q2 2025 up from about $1.3 million in Q4 2022, providing some offset to operating losses.
  • No Revenue Generation: Dyne has consistently reported zero revenue over the last four years, highlighting its pre-commercial stage and dependence on financing for growth.
  • Depreciation and Amortization: Relatively small non-cash charges around $0.4-$0.5 million per quarter indicate minimal fixed asset impact, reflective of a biotech firm's asset-light model.
  • Consistent Net Losses: Dyne reported net losses exceeding $110 million in the most recent quarter (Q2 2025), widening from $44 million in Q1 2023, signaling high burn rates associated with clinical development programs.
  • Operating Cash Flow Negative: Operating activities consumed $94.7 million in cash in Q2 2025, a trend consistent across all recent quarters indicating reliance on external financing for operations.
  • Increasing Total Liabilities: Total liabilities grew from $44 million in Q1 2023 to $157 million by Q2 2025, including significant long-term debt ($98.8 million in Q2 2025), which raises leverage and financial risk.
  • Declining Total Equity: Despite capital raises, total common equity decreased from $478 million in Q1 2023 to $571 million in Q2 2025 on a net basis, influenced by accumulated losses of over $1.17 billion as of Q2 2025.

Summary: Dyne Therapeutics remains a high-burn biotech company in the pre-revenue phase, investing heavily in R&D to advance its pipeline. The company is well-capitalized with over $680 million in combined cash, cash equivalents, and short-term investments as of mid-2025, supported by multiple equity financings. However, widening quarterly net losses and ongoing negative cash flow from operations underscore the continued need for financing until commercialization or partnering opportunities arise. Investors should monitor Dyne's progress toward clinical milestones, cash runway, and potential strategic partnerships given its current financial profile.

08/28/25 11:52 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About Dyne Therapeutics' Financials

When does Dyne Therapeutics' financial year end?

According to the most recent income statement we have on file, Dyne Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Dyne Therapeutics' net income changed over the last 5 years?

Dyne Therapeutics' net income appears to be on an upward trend, with a most recent value of -$317.42 million in 2024, rising from -$14.86 million in 2019. The previous period was -$235.94 million in 2023. Check out Dyne Therapeutics' forecast to explore projected trends and price targets.

What is Dyne Therapeutics' operating income?
Dyne Therapeutics' total operating income in 2024 was -$343.89 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $343.89 million
How has Dyne Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Dyne Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Dyne Therapeutics have?

Dyne Therapeutics' total liabilities were at $61.40 million at the end of 2024, a 16.8% decrease from 2023, and a 2,458.2% increase since 2019.

How much cash does Dyne Therapeutics have?

In the past 5 years, Dyne Therapeutics' cash and equivalents has ranged from $14.63 million in 2019 to $435.45 million in 2024, and is currently $435.45 million as of their latest financial filing in 2024.

How has Dyne Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Dyne Therapeutics' book value per share changed from -5.48 in 2019 to 6.19 in 2024, a change of -212.9%.


Related Companies

This page (NASDAQ:DYN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
What Are Some Strategies to Help Lower RMD Taxes?
Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...
SmartAsset | Sponsoredtc pixel
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...
Banyan Hill Publishing | Sponsoredtc pixel
NVIDIA's Worst Nightmare?
$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...
The Oxford Club | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Trump’s national nightmare is here
AI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...
Porter & Company | Sponsoredtc pixel